Morgan Stanley lowered the firm’s price target on Iqvia (IQV) to $265 from $280 and keeps an Overweight rating on the shares. A “modest beat” in Q3 was led by better-than-expected TAS performance, but this is overshadowed by R&DS headwinds over the next twelve months, including a single large cancellation and two “mega trial delays” to 2025, the analyst tells investors in a post-earnings note. The firm views the risk/reward as attractive on the recent pullback, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IQV:
- Iqvia price target lowered to $265 from $270 at Deutsche Bank
- Iqvia price target lowered to $255 from $270 at TD Cowen
- Iqvia price target lowered to $260 from $290 at BTIG
- Iqvia price target lowered to $223 from $256 at Baird
- Iqvia price target lowered to $255 from $260 at Barclays
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
